5UDE

Crystal Structure of RSV F B9320 DS-Cav1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.001 Å
  • R-Value Free: 0.234 
  • R-Value Work: 0.193 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Zhu, Q.McLellan, J.S.Kallewaard, N.L.Ulbrandt, N.D.Palaszynski, S.Zhang, J.Moldt, B.Khan, A.Svabek, C.McAuliffe, J.M.Wrapp, D.Patel, N.K.Cook, K.E.Richter, B.W.M.Ryan, P.C.Yuan, A.Q.Suzich, J.A.

(2017) Sci Transl Med 9: --

  • DOI: 10.1126/scitranslmed.aaj1928
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is l ...

    Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. We describe the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose. MEDI8897*, a highly potent human antibody, was optimized from antibody D25, which targets the prefusion conformation of the RSV fusion (F) protein. Crystallographic analysis of Fab in complex with RSV F from subtypes A and B reveals that MEDI8897* binds a highly conserved epitope. MEDI8897* neutralizes a diverse panel of RSV A and B strains with >50-fold higher activity than palivizumab. At similar serum concentrations, prophylactic administration of MEDI8897* was ninefold more potent than palivizumab at reducing pulmonary viral loads by >3 logs in cotton rats infected with either RSV A or B subtypes. MEDI8897 was generated by the introduction of triple amino acid substitutions (YTE) into the Fc domain of MEDI8897*, which led to more than threefold increased half-life in cynomolgus monkeys compared to non-YTE antibody. Considering the pharmacokinetics of palivizumab in infants, which necessitates five monthly doses for protection during an RSV season, the high potency and extended half-life of MEDI8897 support its development as a cost-effective option to protect all infants from RSV disease with once-per-RSV-season dosing in the clinic.


    Organizational Affiliation

    Department of Infectious Disease, MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878, USA. suzichj@medimmune.com zhuq@medimmune.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Fusion glycoprotein F0
F
568Human Respiratory syncytial virus 9320Mutation(s): 4 
Find proteins for Q6V2E7 (Human Respiratory syncytial virus 9320)
Go to UniProtKB:  Q6V2E7
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
F
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
Experimental Data & Validation

Experimental Data

Unit Cell:
Length (Å)Angle (°)
a = 170.430α = 90.00
b = 170.430β = 90.00
c = 170.430γ = 90.00
Software Package:
Software NamePurpose
Aimlessdata scaling
PHASERphasing
SBC-Collectdata collection
MOSFLMdata reduction
PDB_EXTRACTdata extraction
Cootmodel building
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2016-12-26 
  • Released Date: 2017-05-17 
  • Deposition Author(s): McLellan, J.S.

Revision History 

  • Version 1.0: 2017-05-17
    Type: Initial release